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AbstrACt
Objective Although public subsidies and physician 
recommendations for vaccination play key roles in 
increasing childhood vaccination coverage, the association 
between them remains uncertain. This study aimed to 
identify the association between awareness of public 
subsidies and recommendations for Haemophilus 
influenzae type b (Hib), Streptococcus pneumoniae 
(pneumococcal conjugate vaccine (PCV)) and human 
papillomavirus (HPV) vaccinations among primary care 
physicians in Japan.
Design This is a cross-sectional study.
setting In 2012, a questionnaire was distributed among 
3000 randomly selected physicians who were members of 
the Japan Primary Care Association.
Participants From the questionnaire, participants 
were limited to physicians who administered childhood 
vaccinations.
Primary and secondary outcome measures The 
primary measures were participants’ awareness of public 
subsidies and their recommendation levels for Hib, PCV 
and HPV vaccines. Multiple logistic regression analysis 
was performed to investigate the association between 
awareness and recommendation, with adjustment for 
possible confounders.
results The response rate was 25.8% (743/2880). Of 
743 physician respondents, 434 were included as analysis 
subjects. The proportions of those who recommended 
vaccinations were 57.1% for Hib, 54.1% for PCV and 
58.1% for HPV. For each vaccine, multivariable analyses 
showed physicians who were aware of the subsidy were 
more likely to recommend vaccination than those who 
were not aware: the adjusted ORs were 4.21 (95% CI 2.47 
to 7.15) for Hib, 4.96 (95% CI 2.89 to 8.53) for PCV and 
4.17 (95% CI 2.00 to 8.70) for HPV.
Conclusions Primary care physicians’ awareness of 
public subsidies was found to be associated with their 
recommendations for the Hib, PCV and HPV vaccines. 
Provision of information about public subsidies to these 
physicians may increase their likelihood to recommend 
vaccination.
IntrODuCtIOn 
Vaccination has proven to be a successful and 
cost-effective health intervention in preven-
tive care.1 Vaccination against Haemoph-
ilus influenzae type b (Hib) is a successful 
example. In the USA, the introduction of 
the Hib vaccine reduced the incidence of 
invasive Hib disease by 99%,2 while in Kenya 
a 93% decline was seen following vaccina-
tion.3 Therefore, many childhood vaccines 
(including Hib) are routinely provided, 
especially in higher income countries, where 
coverage is relatively high.4–8 
In Japan, however, many important 
vaccines, including Hib, Streptococcus pneumo-
niae (seven-valent pneumococcal conjugate 
vaccine (PCV)) and human papillomavirus 
(HPV), were voluntary rather than routine, 
and voluntary vaccinations were not covered 
by the National Immunisation Programme, 
without subsidies by the Government of 
strengths and limitations of this study
 ► This is the first study to focus on the association be-
tween awareness of primary care physicians (PCPs) 
concerning  vaccination subsidies and those PCPs’ 
recommendations for vaccinations for children.
 ► To explore the characteristics of PCPs found associ-
ated with less vaccination recommendation, multi-
variable logistic regression analysis was performed 
with background factors such as the physician’s 
postgraduate year, proportion of paediatric patients 
and experience raising children as a parent.
 ► Although participants were randomly selected, one 
limitation was non-responder bias, which was due 
to the PCPs’ voluntary participation in the survey.
 ► Another limitation was that the generalisability of the 
results to PCPs outside of Japan was unclear.
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Japan.9 These vaccines were introduced in Japan in the 
following years: Hib in 2008, PCV in 2010 and bivalent 
HPV in 2009. There were no public subsidies for them at 
the time they were initially offered. Without public subsi-
dies, patients must pay an out-of-pocket fee, and this cost 
burden may serve as a barrier to receiving vaccination.9 
Routine vaccinations are defined by the Preventive Vacci-
nation Law and scheduled in the National Immunisa-
tion Programme. These vaccinations are not mandatory, 
although the Government of Japan strongly recommends 
them. In principle, vaccinations are administered indi-
vidually, mainly funded by the national and local govern-
ments, and free of charge to recipients in private or 
public facilities at the request of the local government.9 10 
Coverage of traditional, routine vaccinations (eg, those 
for diphtheria, tetanus and measles) is high, and their 
associated diseases are well controlled.9 11 12 However, 
coverage of voluntary vaccinations is much lower, and 
some diseases those vaccinations target are endemic in 
the population.9 12 The Hib vaccine, for example, was first 
introduced to Japan in 2008 on a voluntary basis and had 
estimated coverage of 5%–10% in 2010.13 Therefore, the 
Government of Japan implemented subsidies for local 
governments for Hib, PCV and HPV vaccine fees from 
November 2010, all at the same time.14 The subsidies 
were intended for all children aged over 2 months and 
under 5 years for Hib and PCV, and all girls aged 12–16 
years for HPV.15 Local governments determined the 
subsidy amounts. All local governments have now started 
providing public subsidies for these three vaccines.
It is generally accepted that recommendation of vacci-
nation, to children and their parents by a physician, is 
important for increasing coverage.14 16–19 Primary care 
physicians (PCPs) provide care for all ages, from chil-
dren to older people, and play a key role in childhood 
vaccination as vaccine providers as well as paediatricians. 
However, no previous studies have examined PCPs’ level 
of awareness of public subsidies for childhood vaccines 
in Japan, and the association between this awareness and 
recommendations for vaccination. Therefore, this study 
aimed to examine this association among PCPs in Japan 
for the Hib, PCV and HPV vaccinations.
MethODs
study design, setting and population
This study used a cross-sectional design with data drawn 
from a questionnaire conducted by the Japan Primary 
Care Association (JPCA), the largest academic associa-
tion for PCPs in Japan. The majority of the JPCA physi-
cian members were internists working as PCPs at a clinic 
or hospital. The survey was conducted in September–
November 2012. In total, 3000 physicians were randomly 
selected from among the 5977 JPCA physician members. 
Selection was made using a random number list. Subject 
participants were then selected from among these 3000 
physicians in accordance with the inclusion and exclu-
sion criteria. The inclusion criteria were physicians who 
were JPCA members and who administered childhood 
vaccination (defined as those who administered at least 
one of the Hib, PCV and HPV vaccines in daily medical 
practice). The exclusion criteria were physicians who 
were retired or living out of Japan or within 2 years of 
their postgraduate year, as the latter group are classified 
as ‘junior residents’ in Japan. Questionnaire items were 
based on previous studies.16 17 19–28 We used a self-admin-
istered, anonymous questionnaire design and collected 
data on the participating PCPs’ main practice category, 
practice setting (clinic, hospital or other), local govern-
ment of the practice, population under jurisdiction of the 
local government, and experience as a kindergarten or 
other school physician. Questionnaires were sent to each 
participant by postal mail. Additional details are given 
below.
Patient and public involvement
Patients and other members of the public were not 
involved in this study.
Main exposure
The main exposure of this study was physicians’ aware-
ness of the existence of local government public subsi-
dies for the target vaccine (awareness of public subsidy). 
For each vaccine, respondents were asked ‘Does the local 
government of your place of practice subsidize the vacci-
nation?’ The response options were ‘Yes’, ‘No’ and ‘I 
don’t know’. Answers of ‘Yes’ were defined as ‘awareness 
of public subsidy’. Answers of ‘No’ or ‘I don’t know’ were 
defined as ‘no awareness of public subsidy’.
Main outcome
The main outcome of this study was PCPs’ active recom-
mendation of a target vaccine to children and the 
children’s parents in daily medical practice (‘recommen-
dation’). For each vaccine, the respondents were asked 
‘How do you recommend a target vaccine to vaccinees 
and their parents?’ The response options, on a Likert-type 
scale, were ‘Always recommend’, ‘Maybe recommend’, 
‘No opinion’, ‘Not recommend actively’ and ‘Not recom-
mend’. Answers of ‘Always recommend’ were defined as 
‘recommendation’. ‘Maybe recommend’, ‘No opinion’, 
‘Not recommend actively’ and ‘Not recommend’ were 
defined as ‘no recommendation’.
Possible confounders
Possible confounders were the physician’s sex, postgrad-
uate year, a proportion of paediatric patients (paediatric 
patients in the total patient population) that was high 
(≥10%) or low (<10%), and experience raising children 
as a parent. We added in these data from the question-
naire and also used public information held by the local 
government to investigate the type of the subsidy (full 
subsidy or not) for the three vaccines for each participant.
statistical analyses
Logistic regression analysis was performed for each target 
vaccine (Hib, PCV and HPV) to investigate the association 
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between PCPs’ awareness of a public subsidy for the 
target vaccine and their recommendation of that vaccine. 
Then, multiple logistic regression analysis was performed 
to investigate the association between awareness and 
recommendation, adjusting for possible confounders 
(full subsidy or not, physician’s sex, postgraduate year, 
proportion of paediatric patients and experience raising 
children).
The analysis subjects were set after excluding partici-
pants with missing data for the main exposure, main 
outcome and possible confounders (mentioned above).
All statistical analyses used two-tailed tests of significance, 
with significance set at 0.05. Analyses were performed 
with Stata/SE V.13.1. Sensitivity analysis was performed 
for each vaccine using another method of recategori-
sation to reflect the dichotomisation of the dependent 
variable (recommendation), with the response option 
‘Maybe recommend’ included in ‘recommendation’.
We obtained written informed consent from all partici-
pants before we conducted the survey.
results
study flow and demographics
Of the 3000 randomly selected PCPs, 120 were excluded 
based on the inclusion and exclusion criteria, leaving a 
sample of 2880. We received responses from 743 PCPs, 
for a response rate of 25.8%. The respondents were 
from all 47 prefectures of Japan. Of these respondents, 
480 (64.6%) administered childhood vaccinations. We 
analysed data for 434 (58.4%) after excluding 46 (6.2%) 
with missing data for covariates (figure 1). The majority 
of these PCPs were men, of postgraduate years 11–40, 
reported a clinical category of primary care, reported 
their practice setting as clinic and had experience raising 
children (table 1).
hib vaccine
The characteristics of PCPs were stratified by recommen-
dation of the Hib vaccine and the association between 
awareness of an Hib vaccine public subsidy and vaccina-
tion recommendation (table 2). We found 327 (75.3%) 
PCPs reported awareness of a public subsidy and 248 
(57.1%) recommended the vaccine. PCPs who reported 
awareness were significantly more likely to recommend 
the vaccine than those who were not aware (non-ad-
justed analysis: OR 6.18, 95% CI 3.77 to 10.12, p<0.001; 
multivariable analysis: adjusted OR (AOR) 4.21, 95% CI 
2.47 to 7.15, p<0.001). A higher proportion of paedi-
atric patients and of PCPs with experience raising chil-
dren were positively associated with recommendation. 
Figure 1 Study flow.
Table 1 Participants’ characteristics
Characteristics
Analysis subjects, n=434 Responders, n=743
All physician 
members*, n=5977
n (%) n (%) n (%)
Gender: male 367 (84.6) 624 (84.0) 5071 (84.8)
Postgraduate year 
  3–10 90 (20.7) 153 (20.6) 664 (11.1)
  11–40 318 (73.3) 527 (71.0) 4248 (71.1)
  ≥41 26 (6.0) 62 (8.4) 769 (12.9)
Main practice category: primary care 358 (82.5) 556 (74.8) – 
Practice setting: clinic 307 (70.7) 388 (52.3) – 
Paediatric patients ≥10% 174 (40.1) 186 (26.2) – 
Population of local government ≥50 000 277 (64.0) 527 (71.5) – 
Experience of kindergarten or other school physician 284 (65.4) 403 (54.2) – 
Experience raising children 343 (79.0) 568 (76.5) – 
Main practice category: primary care: answered main practice category as family physician or general practitioner or hospitalist/general 
physician;  paediatric patients: proportion of paediatric patients in the total patient population. 
*Physician members of the Japan Primary Care Association as of September 2012.
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However, a higher postgraduate year was inversely asso-
ciated (table 3).
Pneumococcal conjugate vaccine
The characteristics of PCPs were stratified by recommen-
dation of the PCV and association between awareness of 
a PCV public subsidy and vaccination recommendation 
(table 2). Overall, 315 (72.6%) PCPs reported aware-
ness of a public subsidy and 235 (54.1%) recommended 
the vaccine. Physicians who reported awareness were 
significantly more likely to recommend vaccination than 
those who were not aware (non-adjusted analysis: OR 
8.03, 95% CI 4.84 to 13.32, p<0.001; multivariable anal-
ysis: AOR 4.96, 95% CI 2.89 to 8.53, p<0.001). A higher 
proportion of paediatric patients and of PCPs with expe-
rience raising children were positively associated with 
vaccination recommendation, and higher postgraduate 
year was inversely associated (table 4).
hPV vaccine
The characteristics of PCPs stratified by recommenda-
tion of the HPV vaccine and the association between the 
awareness of an HPV vaccine public subsidy and vaccina-
tion recommendation are presented (table 2). We found 
Table 2 Primary care physicians’ awareness of public subsidies and recommendation levels for Hib vaccine, seven-valent 
PCV and HPV vaccine
Awareness of 
public subsidy for 
each vaccine Total, n (%)
n=434
Recommendation level for each vaccine, n (%)
Always 
recommend
May be 
recommend
No 
opinion
Not recommend 
actively Not recommend
Hib vaccine
  Awareness (+) 327 (75.3) 221 (67.6) 78 (23.9) 23 (7.0) 3 (0.9) 2 (0.6)
  Awareness (−) 107 (24.7) 27 (25.2) 40 (37.4) 27 (25.2) 8 (7.5) 5 (4.7)
  Total 434 (100) 248 (57.1) 118 (27.2) 50 (11.5) 11 (2.5) 7 (1.6)
PCV 
  Awareness (+) 315 (72.6) 211 (67.0) 77 (24.4) 22 (7.0) 4 (1.3) 1 (0.3)
  Awareness (−) 119 (27.4) 24 (20.2) 45 (37.8) 36 (30.3) 8 (6.7) 6 (5.0)
  Total 434 (100) 235 (54.1) 122 (28.1) 58 (13.4) 12 (2.8) 7 (1.6)
HPV vaccine
  Awareness (+) 389 (89.6) 241 (62.0) 121 (31.1) 19 (4.9) 6 (1.5) 2 (0.5)
  Awareness (−) 45 (10.4) 11 (24.4) 18 (40.0) 13 (28.9) 3 (6.7) 0 (0)
  Total 434 (100) 252 (58.1) 139 (32.0) 32 (7.4) 9 (2.1) 2 (0.5)
Hib, Haemophilus influenzae type b; HPV, human papillomavirus; PCV, pneumococcal conjugate vaccine.
Table 3 Association between primary care physicians’ characteristics and recommendation of Hib vaccine
Variable
Recommendation for Hib vaccine, n (%) Non-adjusted analysis Multivariable analysis
Total, n=434
Recommendation 
(+), n=248
Recommendation 
(−), n=186 OR 95% CI P values AOR 95% CI P values
Awareness of public 
subsidy for Hib 
vaccine
327 (75.4) 221 (89.1) 106 (57.0) 6.18 3.77 to 
10.12
<0.001 4.21 2.47 to 7.15 <0.001
Full subsidy 371 (85.5) 209 (84.3) 162 (87.1) – – – 0.76 0.41 to 1.41 0.39
Male 367 (84.6) 205 (82.7) 162 (87.1) – – – 0.97 0.52 to 1.80 0.93
Postgraduate year 
  3–10 90 (20.7) 68 (27.4) 22 (11.8) – – – Ref
  11–40 318 (73.3) 168 (67.7) 150 (80.6) – – – 0.32 0.17 to 0.61 <0.001
  ≥41 26 (6.0) 12 (4.8) 14 (7.5) – – – 0.19 0.07 to 0.53 0.001
Paediatric 
patients ≥10%
174 (40.1) 127 (51.2) 47 (25.3) – – – 2.16 1.37 to 3.41 0.001
Experience raising 
children
343 (79.0) 205 (82.7) 138 (74.2) – – – 1.96 1.10 to 3.47 0.021
Multivariable analysis: multiple logistic regression analysis adjusted with above variables; non-adjusted analysis: logistic regression analysis; 
paediatric patients: proportion of paediatric patients in the total patient population.
AOR, adjusted OR; Hib, Haemophilus influenza type b; Ref, reference.
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that 389 (89.6%) PCPs reported awareness of the public 
subsidy and 252 (58.1%) recommended the vaccine. 
Physicians who reported awareness were significantly 
more likely to recommend vaccination than those who 
were not aware (non-adjusted analysis: OR 5.03, 95% CI 
2.47 to 10.24, p<0.001; multivariable analysis: AOR 4.17, 
95% CI 2.00 to 8.70, p<0.001). Experience raising chil-
dren was positively associated with recommendation, 
and higher postgraduate year was inversely associated 
(table 5).
sensitivity analysis
The sensitivity analysis included recategorised 
outcomes for recommendation of vaccines. The results 
demonstrated that for each vaccine, PCPs who reported 
awareness of a subsidy were significantly more likely to 
recommend vaccination than those who were not aware: 
AOR 3.52 (95% CI 1.91 to 6.49, p<0.001) for the Hib 
vaccine, 4.42 (95% CI 2.45 to 7.98, p<0.001) for the PCV, 
and 5.08 (95% CI 2.29 to 11.25, p<0.001) for the HPV 
vaccine.
DIsCussIOn
This is the first investigation focused on the proportion 
of PCPs who have awareness of vaccination subsidies and 
their recommendations of Hib, PCV and HPV vaccines, 
Table 4 Association between primary care physicians’ characteristics and recommendation of seven-valent PCV
Variable
Recommendation for PCV, n (%) Non-adjusted analysis Multivariable analysis
Total, n=434
Recommendation 
(+), n=235
Recommendation 
(−), n=199 OR 95% CI P values AOR 95% CI P values
Awareness of 
public subsidy for 
PCV
315 (72.6) 211 (89.8) 104 (52.3) 8.03 4.84 to 13.32 <0.001 4.96 2.89 to 8.53 <0.001
Full subsidy 369 (85.0) 194 (82.6) 175 (87.9) – – – 0.62 0.33 to 1.17 0.14
Male 367 (84.6) 194 (82.6) 173 (86.9) – – – 0.98 0.52 to 1.83 0.94
Postgraduate 
year 
  3–10 90 (20.7) 66 (28.1) 24 (12.1) – – – Ref
  11–40 318 (73.3) 158 (67.2) 160 (80.4) – – – 0.29 0.15 to 0.56 <0.001
  ≥41 26 (6.0) 11 (4.7) 15 (7.5) – – – 0.18 0.06 to 0.54 0.002
Paediatric 
patients ≥10%
174 (40.1) 127 (54.0) 47 (23.6) – – – 2.5 1.57 to 3.98 <0.001
Experience 
raising children
343 (79.0) 197 (83.8) 146 (73.4) – – – 2.61 1.43 to 4.74 0.002
Multivariable analysis: multiple logistic regression analysis adjusted with above variables; non-adjusted analysis: logistic regression analysis; 
paediatric patients: proportion of paediatric patients in the total patient population. 
AOR, adjusted OR; PCV, pneumococcal conjugate vaccine; Ref, reference.
Table 5 Association between primary care physicians’ characteristics and recommendation of HPV vaccine
Variable
Recommendation for HPV vaccine, n (%) Non-adjusted analysis Multivariable analysis
Total, n=434
Recommendation 
(+), n=252
Recommendation 
(−), n=182 OR 95% CI P values AOR 95% CI P values
Awareness of 
public subsidy for 
HPV vaccine
389 (89.6) 241 (95.6) 148 (81.3) 5.03 2.47 to 10.24 <0.001 4.17 2.00 to 8.70 <0.001
Full subsidy 385 (88.7) 225 (89.3) 160 (87.9) – – – 1.25 0.66 to 2.35 0.49
Male 367 (84.6) 210 (83.3) 157 (86.3) – – – 0.96 0.54 to 1.72 0.9
Postgraduate year 
  3–10 90 (20.7) 61 (24.2) 29 (15.9) – – – Ref
  11–40 318 (73.3) 174 (69.1) 144 (79.1) – – – 0.47 0.27 to 0.82 0.008
  ≥41 26 (6.0) 17 (6.8) 9 (5.0) – – – 0.72 0.27 to 1.97 0.53
Paediatric 
patients ≥10%
174 (40.1) 112 (44.4) 62 (34.1) – – – 1.34 0.88 to 2.03 0.17
Experience raising 
children
343 (79.0) 211 (83.7) 132 (72.5) – – – 2.21 1.31 to 3.72 0.003
Multivariable analysis: multiple logistic regression analysis adjusted with above variables; non-adjusted analysis: logistic regression analysis; 
paediatric patients: proportion of paediatric patients in the total patient population.
AOR, adjusted OR; HPV, human papillomavirus; Ref, reference.
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and the association between awareness of such subsidies 
and recommendation of vaccination. We found a positive 
association between physicians’ awareness of the subsidy 
and their recommendation of vaccination.
These vaccines were recently introduced in Japan: Hib 
in 2008, PCV in 2010, bivalent HPV vaccine in 2009 and 
quadrivalent HPV vaccine in 2011. The subsidies for these 
three vaccines were implemented from November 2010. 
When subsidies were offered, information about them 
was conveyed to patients/families and providers through 
public outlets such as local government websites or public 
relations magazines. Additionally, public health nurses 
informed parents at the time the children received health 
check-ups. Local governments also sent notices about the 
subsidies to each medical facility and medical association. 
Gathering of data for this study was conducted in 2012, 
meaning the results reflect the actual clinical situation 
after the new introduction of vaccines among PCPs in 
Japan. The estimated coverage rates for these vaccines in 
2012 were 70%–90% for Hib,29 30 80%–90% for PCV29 31 
and 65%–75% for HPV.32 33 Our study showed that even 
among PCPs who administered childhood vaccinations, 
not all were aware that subsidies existed and not all 
actively recommended vaccination. Vaccination fees serve 
as a barrier to vaccination for patients,9 and PCPs need 
access to information about vaccine costs, especially with 
regard to public subsidies. Of the three vaccines studied, 
the HPV vaccine was most commonly recognised by the 
surveyed PCPs. This was also the most expensive of these 
vaccines, and healthcare professionals have cited finan-
cial concerns as a barrier to vaccination.34 It therefore 
appears PCPs need to be more aware of available subsi-
dies for this vaccination.
However, the proportions of PCPs’ recommendations 
were similar for all three vaccines. These proportions 
were low when compared with those in other countries; 
for instance, 68% of family physicians in the USA adopted 
recommendations for PCV vaccination in 2001, 1 year after 
the Centers for Disease Control and Prevention recom-
mended it.24 In 2008, 50% of the family physicians who 
administered the HPV vaccine in the USA strongly recom-
mended the vaccine for girls aged 11–12 years and 85% 
for girls aged 13–15 years.25 However, studies conducted 
in 2011 reported that 40.0% of physicians (family physi-
cians, paediatricians and obstetricians/gynaecologists) in 
the USA always recommended HPV vaccination, as did 
45.6% of general practitioners in France.35 36 Although 
the proportion of PCP recommendations of vaccination 
may differ by country and time of year, recommendations 
from healthcare providers are important for patients, 
especially with regard to new vaccine.37
For all three vaccines studied, there was a statistically 
significant association between PCPs’ awareness of a 
public subsidy and their recommendation of vaccination. 
In comparing PCPs who had no awareness of subsidies 
with those who were aware, the AOR for recommenda-
tion was 4.21 for the Hib vaccine, 4.96 for the PCV and 
4.17 for the HPV vaccine (tables 3–5). These results 
suggest awareness is an important factor behind vaccina-
tion recommendation. The robustness of our results was 
demonstrated in sensitivity analysis using another method 
of recategorisation. Recent studies have highlighted that 
the cost of vaccination is also a barrier for physicians to 
recommend vaccination.38 39 Multiple logistic regression 
analysis showed that, in addition to awareness, a higher 
proportion of paediatric patients were positively associ-
ated with recommendation of Hib and PCV vaccination, 
and experience raising children was positively associated 
with recommendation of all three vaccines (tables 3–5). 
These results suggest provision of information or expe-
rience with children on a regular basis may affect PCPs’ 
recommendations. We also found that a higher post-
graduate year was inversely associated with recommenda-
tion (tables 3–5). The Hib, PCV and HPV vaccines were 
recently introduced in Japan, and PCPs with a lower post-
graduate year may have greater interest in or knowledge 
about these vaccines because of their more recent educa-
tion or training. This suggests providing information 
about public subsidies to older PCPs may be more effec-
tive than providing information to younger PCPs. A study 
conducted after the introduction of the Hib vaccine in the 
USA reported younger physicians were more accepting of 
the vaccine than older ones; this supports our results.40
Our study also suggested PCPs’ awareness of public 
subsidies, their having more paediatric patients and their 
having experience raising children were important factors 
in increasing their recommendations of childhood vacci-
nation. For voluntary vaccinations without public subsi-
dies, governmental introduction of a public subsidy may 
play an important role in increasing coverage.9 39 41 For 
vaccinations already subsidised, implementing a plan to 
inform PCPs about the subsidy and providing PCPs with 
updated education and information about the vaccine 
and subsidy system (considering physician characteristics, 
especially age and those with fewer paediatric patients) 
may increase the proportion of those who recommend 
vaccination.
This study did have some limitations. First, there was 
a potential non-responder bias due to the low response 
rate. The proportion of younger PCPs (postgraduate 
years 3–10) was higher among responders in this study 
than in the target population (table 1); therefore, PCPs 
who more actively promoted vaccination may have been 
more likely to respond. The actual levels of PCPs’ aware-
ness and recommendations may be lower. Second, factors 
such as knowledge of vaccination, including vaccine safety 
and effectiveness, PCPs’ circumstances or abilities, and 
PCPs’ experience may have affected their recommenda-
tion behaviour.36 We did not investigate PCPs’ knowledge 
of vaccine safety and effectiveness; therefore, the asso-
ciation between their knowledge of vaccines and their 
vaccination recommendation behaviour should be inves-
tigated in a future study.39 To account for this limitation, 
we limited our analysis to PCPs who administered child-
hood vaccinations and we adjusted for the proportion of 
paediatric patients (factors related to PCPs’ medical care 
7Sakanishi Y, et al. BMJ Open 2018;8:e020923. doi:10.1136/bmjopen-2017-020923
Open access
circumstances and abilities). As is a general limitation 
of observational studies, we did not evaluate the effect 
of unknown confounding factors. Finally, although the 
study participants were physician members of the JPCA, 
the largest society for PCPs in Japan, generalisability of 
the results to PCPs outside of Japan was unclear. Vacci-
nation policy in Japan also changed after this study was 
conducted9 10; therefore, an interannual survey is needed 
to accurately comprehend the current situation of vacci-
nation among PCPs.
COnClusIOns
In this study, we described the proportion of PCPs’ aware-
ness of existence of public subsidies and their recommen-
dations for the Hib, PCV and HPV vaccines, and revealed 
a significant association between awareness and recom-
mendation. Even among PCPs who administered child-
hood vaccinations, there was variability in these two areas. 
Our results suggest that informing PCPs about public 
subsidies may increase their recommendations for these 
vaccines and improve vaccination coverage.
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